SI
SLNO

Sofinnova Investments’s Soleno Therapeutics SLNO Stock Holding History

Sofinnova Investments’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,689
Closed -$492K – 81
2026
Q1 		$492K Buy
14,689
+2,275
+18% +$89.2K 0.02% 72
2025
Q4 		$575K Sell
12,414
-153,867
-93% -$8.44M 0.02% 59
2025
Q3 		$11.2M Sell
166,281
-248,938
-60% -$18.5M 0.61% 43
2025
Q2 		$34.8M Sell
415,219
-69,252
-14% -$5.18M 2.13% 17
2025
Q1 		$34.6M Sell
484,471
-272,777
-36% -$13.3M 2.26% 13
2024
Q4 		$34M Buy
757,248
+170,904
+29% +$8.86M 2.48% 14
2024
Q3 		$29.6M Buy
586,344
+31,985
+6% +$1.53M 2.35% 12
2024
Q2 		$22.6M Buy
554,359
+403,584
+268% +$17.1M 1.18% 27
2024
Q1 		$6.45M Buy
150,775
+149,575
+12,465% +$6.77M 0.36% 46
2023
Q4 		$48.3K Buy
+1,200
New +$34.1K ﹤0.01% 61

Sofinnova Investments's SLNO Position: Q2 2026 in Review

Sofinnova Investments sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 14,689 shares — an estimated $492K sold.

Sofinnova Investments first reported a position in SLNO in Q4 2023 and held it in 10 quarters. The position peaked at $34.8M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Sofinnova Investments reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sofinnova Investments sold 14,689 Soleno Therapeutics shares in Q2 2026, an estimated $492K.
  • Sofinnova Investments first reported a position in Soleno Therapeutics in Q4 2023 and held it in 10 quarters.
  • Sofinnova Investments's Soleno Therapeutics position peaked at $34.8M in Q2 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.